• ME Therapeutics director John Priatel lifted his stake to about 16.21% on a partially diluted basis following a private placement, warrants, options.
• He bought 294,118 units for $500,000.60 at $1.7 per unit, taking common shares held to 4,469,261.
• Holdings also include 294,118 warrants, 250,000 options; prior stake was about 13.89% on a non-diluted basis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ME Therapeutics Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260717445500) on July 17, 2026, and is solely responsible for the information contained therein.